SCHEMBL5758000

SCHEMBL5758000

CNC(=O)c1ccc(O)c(OC)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.68
KMT2A Q03164 2/20 0.68
SLC22A6 Q4U2R8 1/20 0.68
SLC22A8 Q8TCC7 1/20 0.68
RAB9A P51151 1/20 0.68
HTT P42858 1/20 0.66
HSD17B2 P37059 1/20 0.57
CYP1A2 P05177 1/20 0.55
HSP90AA1 P07900 1/20 0.55
HSP90AB1 P08238 1/20 0.55
BLM P54132 1/20 0.55
PLK1 P53350 1/20 0.55
KDM4E B2RXH2 1/20 0.54
POLB P06746 1/20 0.54
HDAC6 Q9UBN7 1/20 0.54
AURKB Q96GD4 1/20 0.53
ALDH1A1 P00352 2/20 0.53
HPGD P15428 2/20 0.53
GAA P10253 1/20 0.51
MAPT P10636 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10649335 0.86 MEN1 (0.64) MEN1KMT2ASLC22A6SLC22A8RAB9A
SCHEMBL1437123 0.86 SLC22A6 (0.68) MEN1KMT2ASLC22A6SLC22A8RAB9A
SCHEMBL19519009 0.86 PDE4D (0.60) MEN1KMT2ASLC22A6SLC22A8RAB9A
SCHEMBL4151619 0.85 CYP1A2 (0.66) MEN1KMT2ACYP1A2PLK1KDM4E
SCHEMBL28325208 0.85 MEN1 (0.62) MEN1KMT2ASLC22A6SLC22A8RAB9A
Hydrochloric Acid SCHEMBL28155688 0.84 SLC22A6 (0.66) MEN1KMT2ASLC22A6SLC22A8RAB9A
SCHEMBL2086007 0.84 MEN1 (0.66) MEN1KMT2ASLC22A6SLC22A8RAB9A
SCHEMBL2664428 0.84 MEN1 (0.66) MEN1KMT2ASLC22A6SLC22A8RAB9A
SCHEMBL16076892 0.83 FYN (0.52) MEN1KMT2ASLC22A6SLC22A8RAB9A
SCHEMBL9103250 0.82 TAS1R3 (0.56) MEN1KMT2AHTTCYP1A2PLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025245367-A1 INHIBITING CATECHOL-O-METHYLTRANSFERASE (COMT) PSY THERAPEUTICS, INC. (US) 2025-11-27 WO disclosed
US-20210371413-A1 POLYCYCLIC AMIDES AS CYTOTOXIC AGENTS Pheon Therapeutics Ltd. (GB) 2021-12-02 US disclosed
WO-2017098257-A1 PBD ANTIBACTERIAL AGENTS KING'S COLLEGE LONDON (GB) 2017-06-15 WO disclosed
US-20160032047-A1 Peg-based adhesive phenylic derivatives and methods of synthesis and use DSM IP ASSETS B.V. (NL) 2016-02-04 US disclosed
US-8962600-B2 Neuroprotective compounds and their use THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) 2015-02-24 US disclosed
US-20120329755-A1 GLYCOMIMETIC INHIBITORS OF THE PA-IL LECTIN, PA-IIL LECTIN OR BOTH THE LECTINS FROM PSEUDOMONAS GLYCOMIMETICS, INC. (US) 2012-12-27 US disclosed
US-8258290-B2 Glycomimetic inhibitors of the PA-IL lectin, PA-IIL lectin or both the lectins from pseudomonas GLYCOMIMETICS, INC. (US) 2012-09-04 US disclosed
US-20100041626-A1 GLYCOMIMETIC INHIBITORS OF THE PA-IL LECTIN, PA-IIL LECTIN OR BOTH THE LECTINS FROM PSEUDOMONAS GLYCOMIMETICS, INC. (US) 2010-02-18 US disclosed
WO-2007021721-A2 GLYCOMIMETIC INHIBITORS OF THE PA-IL LECTIN, PA-IIL LECTIN OR BOTH THE LECTINS FROM PSEUDOMONAS GLYCOMIMETICS, INC. (US) 2007-02-22 WO disclosed
EP-1663234-A1 PIPERAZINE DERIVATIVES FOR THE TREATMENT OF HIV INFECTIONS Pfizer Limited (GB) 2006-06-07 EP disclosed
WO-2005121094-A1 PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTI-HIV-AGENTS PFIZER LIMITED (GB) 2005-12-22 WO disclosed
US-20050043300-A1 Piperazine derivatives PFIZER INC. 2005-02-24 US disclosed
WO-2005016344-A1 PIPERAZINE DERIVATIVES FOR THE TREATMENT OF HIV INFECTIONS PFIZER LIMITED (GB) 2005-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041626-A1 GLYCOMIMETIC INHIBITORS OF THE PA-IL LECTIN, PA-IIL LECTIN OR BOTH THE LECTINS FROM PSEUDOMONAS MASP2, SERPINB1, SIGLEC7 MEN1 3930/4885KMT2A 4322/4885SLC22A6 1823/4885
US-20210371413-A1 POLYCYCLIC AMIDES AS CYTOTOXIC AGENTS PBRM1, NFATC1, ACIN1 MEN1 1506/4885KMT2A 957/4885SLC22A6 2811/4885
US-20050043300-A1 Piperazine derivatives CD4, CCR5, RRP15 MEN1 4800/4885KMT2A 2921/4885SLC22A6 3490/4885
US-20120329755-A1 GLYCOMIMETIC INHIBITORS OF THE PA-IL LECTIN, PA-IIL LECTIN OR BOTH THE LECTINS FROM PSEUDOMONAS MASP2, SERPINB1, SIGLEC7 MEN1 3930/4885KMT2A 4322/4885SLC22A6 1823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.